>북미 및 유럽 여성 건강 시장, 치료(의약품 및 기기), 적응증(암, 생식 건강, 비뇨기 질환, 갑상선 기능 저하증, 폐경 후 증후군 및 기타), 제공 방식(처방전 및 일반 의약품), 약물 유형(브랜드 및 제네릭), 치료 유형(일반 건강 관리 및 웰빙, 임신 및 간호 관리, 골반 및 자궁 건강 관리 및 기타), 최종 사용자(병원 및 진료소, 산부인과 센터, 재택 치료 시설, 연구소 및 기타), 유통 채널(직접 입찰, 소매 판매, 온라인 판매 및 기타) - 업계 동향 및 2031년까지의 예측.
북미 및 유럽 여성 건강 시장 분석 및 규모
여성들 사이에서 만성 쇠약 상태의 증가율과 건강에 영향을 미치는 라이프스타일 및 환경 요인의 변화는 시장 수요를 촉진하는 요인 중 일부입니다. 또한, 전반적인 건강과 웰빙을 개선하려는 정부 이니셔티브는 시장 성장을 더욱 촉진하고 있습니다. 시장에 영향을 미치는 주요 제약은 특정 제품과 관련된 부작용입니다. 불임 치료에 대한 인식과 수용이 증가하면서 시장 성장의 기회가 되고 있습니다. 높은 산모 사망률과 이환율은 시장 성장에 도전이 되고 있습니다.
북미 및 유럽 여성 건강 시장은 2023년 91억 2,000만 달러에서 2031년 164억 9,000만 달러로 성장할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 8.0%의 CAGR로 성장할 것으로 예상됩니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2024년부터 2031년까지 |
|
기준 연도 |
2023 |
|
역사적 연도 |
2022 (2016-2021년까지 사용자 정의 가능) |
|
양적 단위 |
매출 (USD) 10억 |
|
다루는 세그먼트 |
치료(약물 및 기기), 적응증(암, 생식 건강, 비뇨기 질환, 갑상선 기능 저하증, 폐경 후 증후군 및 기타), 제공 방식(처방전 및 일반 의약품), 약물 유형(브랜드 및 제네릭), 관리 유형(일반 건강 관리 및 웰빙, 임신 및 간호 관리, 골반 및 자궁 건강 관리 및 기타), 최종 사용자(병원 및 진료소, 산부인과 센터, 홈 케어 시설, 연구소 및 기타), 유통 채널(직접 입찰, 소매 판매, 온라인 판매 및 기타) |
|
적용 국가 |
미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 스페인, 스위스, 네덜란드, 벨기에, 러시아, 터키, 영국 및 기타 유럽 국가 |
|
시장 참여자 포함 |
Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc., Pfizer Inc. 등이 있습니다. |
시장 정의
"여성 건강"으로 알려진 의학 및 의료 서비스 분야는 모든 연령대의 여성에게 영향을 미치는 특정한 생물학적, 생리적, 심리적 요구 사항과 문제에 전념합니다. 여성 특정 웰빙 증진, 산부인과 치료, 생식 건강 및 성 건강과 관련된 다양한 주제를 다룹니다. 또한 월경, 피임, 임신, 출산, 폐경 및 골다공증, 자궁 내막증 , 유방암 및 난소암과 같은 질병과 관련된 성별별 건강 문제가 여성 건강에 포함됩니다. 여성 건강은 또한 의료 결과, 접근성 및 품질의 성별 격차를 해소하기 위한 검진, 예방 치료 및 개입에 중점을 둡니다.
북미 및 유럽 여성 건강 시장 역학
이 섹션에서는 시장 동인, 기회, 과제 및 제약을 이해하는 것을 다룹니다. 이 모든 내용은 아래에서 자세히 설명합니다.
운전자
- 여성들 사이에서 만성 쇠약 상태의 증가율
고령화 인구는 북미와 유럽의 여성에서 만성 질환의 발병률이 증가하는 주요 요인입니다. 여성은 남성보다 당뇨병, 골다공증, 심혈관 질환 및 일부 유형의 암과 같은 연령 관련 질병을 경험할 가능성이 더 높습니다. 여성에게만 나타나는 의학적 질환의 수가 증가함에 따라 조기 발견, 효율적인 치료 및 유리한 결과를 목표로 하는 새로운 진단 기술, 치료적 접근 방식 및 예방 조치에 대한 수요가 증가하고 있습니다. 의료 서비스 제공자, 제약 회사 및 의료 기기 제조업체는 여성의 변화하는 요구를 더 잘 충족시키기 위해 R&D에 대한 투자를 늘려 이러한 요구에 대응하고 있습니다. 이는 제품 제공을 확대하고 의료 서비스 제공 모델을 개선하여 이루어집니다.
북미와 유럽에서 만성 질환이 여성 건강 결과에 미치는 영향을 완화하려면 건강의 사회적 결정 요인을 다루고, 의료 서비스에 대한 접근성을 개선하고, 건강한 행동을 장려하는 공중 보건 조치가 필요합니다. 의료 기관, 입법자, 연구자 및 커뮤니티는 골다공증, 자궁 내막증, 유방암 및 난소암을 포함한 질병을 해결하기 위해 함께 노력해야 하며, 이는 전 세계적으로 여성에게 계속 영향을 미칩니다. 따라서 여성 사이에서 만성 쇠약 상태의 증가율이 시장 성장의 주요 원동력입니다.
- R&D 활동의 결과로 개발되는 혁신 기술
여성 건강 관리 분야는 다양한 질환의 진단, 치료 및 관리에 혁신적인 솔루션을 제공하는 의료 기술의 혁명적 발전으로 인해 변화하고 있습니다. 이러한 발전은 표적 의약품, 최소 침습 수술 방법, 정밀 의학 및 재생 의학 전략과 같은 광범위한 기술을 포괄합니다.
이러한 새로운 치료법의 수용은 전문적인 의료 서비스에 대한 수요, 의료 서비스 제공자, 학계, 기술 개발자 간의 협력, 인프라와 인력 개발에 대한 투자 등을 촉진하고 있습니다.
모바일 건강 앱, 원격 진료, 원격 모니터링을 포함한 디지털 건강 기술의 통합은 치료에 대한 접근성을 개선하고 여성이 의료 산업에서 적극적인 역할을 할 수 있도록 합니다. 그 결과 여성 건강 시장은 북미와 유럽 전역에서 빠르게 확장되고 혁신되고 있습니다. 새로운 기술은 환자 결과, 치료 품질 및 전반적인 의료 제공의 발전을 촉진하고 있습니다. 따라서 R&D 활동의 결과로 개발되고 있는 혁신적인 기술이 시장 성장을 촉진하고 있습니다.
기회
- 정신 건강에 대한 인식 증가
우울증, 불안, 산후 우울증, 섭식 장애를 포함한 정신 건강 문제는 종종 생물학적, 심리적, 사회적 요인이 결합되어 여성에게 불균형적으로 영향을 미칩니다. 정신 건강 문제에 대한 이러한 높아진 인식은 혁신적인 치료법, 디지털 정신 건강 도구, 여성의 고유한 요구에 맞게 특별히 맞춤화된 지원 서비스에 대한 수요를 증가시켰습니다.
따라서 이러한 요구에 부응하여 여성의 정신 건강을 전문으로 하는 기업은 여성의 정신 웰빙을 개선하고 정신 건강 장애를 해결하는 것을 목표로 하는 다양한 솔루션을 개발하고 제공할 기회를 갖게 됩니다.
디지털 정신 건강 도구와 여성의 특정 요구에 맞춰진 지원 서비스를 통해 시장의 이해 관계자들은 다양한 커뮤니티의 여성들의 정신 건강 결과를 개선하고 삶의 질을 향상시키는 데 기여할 수 있습니다. 이는 혁신적인 치료법 개발에 투자함으로써 이루어집니다. 북미와 유럽의 여성들 사이에서 정신 건강과 웰빙의 중요성에 대한 인식이 커지면서 시장 성장에 큰 기회가 생깁니다.
제약/도전
- 특정 제품과 관련된 부작용
최근 몇 년 동안 여성 건강을 겨냥한 개인 관리 용품, 의료 기기, 약물과 같은 다양한 제품의 효능과 안전성에 대한 우려가 표면화되었습니다. 소비자, 의료 종사자, 규제 기관은 호르몬 대체 요법, 피임 방법, 성형 수술을 포함한 이러한 제품의 부작용에 대해 경각심을 갖고 있습니다.
여성 건강에 대한 약물 사용의 부작용은 흔하며, 이는 면밀한 관찰, 정보에 입각한 동의, 개별화된 치료 계획의 가치를 강조합니다. 의료 전문가는 환자의 선호도와 나이, 병력, 합병증을 고려하여 약물 치료의 장단점을 신중하게 따져봐야 합니다. 따라서 특정 제품과 관련된 부작용은 시장 성장을 제한할 것으로 예상됩니다.
- 생식 건강에 영향을 미치는 환경 노출
산업화, 도시화, 농업, 제조, 소비자 제품에서의 광범위한 화학 물질 사용으로 인해 북미와 유럽의 여성 생식 건강에 환경 노출이 상당한 과제로 떠올랐습니다. 플라스틱과 개인 관리 용품에서 발견되는 BPA, 프탈레이트, 살충제와 같은 내분비 교란 화학 물질(EDC)에 노출되면 불임, 월경 불순, 호르몬 불균형이 초래될 수 있습니다. 산업 배출물과 자동차 배기 가스로 인한 대기 오염은 조산 및 저체중 출산과 같은 부정적인 임신 결과에 기여합니다. 여성 건강 시장의 이해 관계자는 다양한 커뮤니티의 여성을 위해 위험을 완화하고 생식 건강을 보호할 수 있습니다. 인식 제고, 예방 조치 시행, 환경 오염 감소 정책 옹호를 통해 이를 수행할 수 있습니다. 생식 건강에 영향을 미치는 환경 노출은 시장 성장에 대한 다면적인 과제를 나타냅니다.
최근 개발 사항
- 2023년 11월, 루핀은 MENA 지역과 다양한 글로벌 시장에 진출한 저명한 제약 제조업체인 Amman Pharmaceuticals Industries(Amman Pharma)와 독점적 파트너십을 체결했습니다. 이 협력에는 Lucentis의 바이오시밀러인 Ranibizumab에 대한 마케팅 및 상용화 권리가 포함됩니다. 이 전략적 파트너십을 통해 루핀은 새로운 지역에 진출하고 시장 입지를 확대하여 궁극적으로 제약 산업에서 회사의 입지를 강화할 수 있습니다.
- 2023년 7월, GSK plc.는 미국 식품의약국(FDA)이 FDA 승인 검사에서 결정된 미세위성 불안정성-높음(MSI-H) 또는 불일치 복구 결핍(dMMR)인 성인 원발성 진행성 또는 재발성 자궁내막암 환자의 치료를 위한 단일제로 Jemperli(dostarlimab)를 승인했다고 발표했습니다. 이를 통해 회사는 제품 제공을 확대할 수 있었습니다.
- 2022년 8월, Myovant Sciences와 Pfizer Inc.는 미국 식품의약국(FDA)이 MYFEMBREE(relugolix 40mg, estradiol 1mg, norethindroneacetate 0.5mg)를 폐경 전 여성의 자궁 내막증과 관련된 중등도에서 중증의 통증을 관리하기 위한 1일 1회 복용하는 단일 알약 요법으로 승인했다고 발표했습니다. 치료 과정은 최대 24개월까지 지속될 수 있습니다. 이를 통해 회사는 제품 범위를 확장할 수 있었습니다.
- 2020년 11월, 특수 제약 회사인 Avion Pharmaceuticals(Alora Pharmaceuticals, LLC의 자회사) LLC가 Aspen Pharma USA Inc. 및 Aspen Global Incorporated와 독점 라이선스 및 상용화 계약을 체결했습니다. 이 계약은 Avion에 9가지 복합 에스트로겐의 유일한 식물 유래 블렌드인 Cenestin(합성 복합 에스트로겐, A) 정제를 재출시할 독점권을 부여합니다.
- 2020년 6월, AbbVie Inc.는 Neurocrine Biosciences, Inc.와 협력하여 미국 식품의약국(FDA)이 ORIAHNN(elagolix, estradiol, norethindroneacetate capsules; elagolix capsules)에 대한 승인을 부여했으며, 최대 24개월의 치료 기간이 허용되었다고 발표했습니다. ORIAHNN은 폐경 전 여성의 자궁 근종과 관련된 과다한 월경 출혈을 해결하기 위한 FDA 승인을 받은 최초의 비수술적 경구 치료 옵션입니다. 이 승인은 회사의 여성 건강 약물 포트폴리오를 확장하고 Neurocrine Biosciences를 이 분야의 핵심 기업으로 자리매김하게 했습니다.
북미 및 유럽 여성 건강 시장 범위
북미와 유럽 여성 건강 시장은 치료, 적응증, 전달 방식, 약물 유형, 케어 유형, 최종 사용자, 유통 채널을 기준으로 하는 7개의 주요 세그먼트로 분류됩니다. 이러한 세그먼트의 성장은 산업의 주요 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내릴 수 있는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.
치료
- 약제
- 장치
북미와 유럽 여성 건강 시장은 치료를 기준으로 약물과 의료기기로 구분됩니다.
표시
- 암
- 생식 건강
- 비뇨기 질환
- 갑상선 기능 저하증
- 폐경 후 증후군
- 기타
북미와 유럽 여성 건강 시장은 증상에 따라 암, 생식 건강, 비뇨기 질환, 갑상선 기능 저하증, 폐경 후 증후군 등으로 구분됩니다.
배달 모드
- 처방
- 카운터 너머
북미와 유럽 여성 건강 시장은 전달 방식을 기준으로 처방약과 일반 의약품으로 구분됩니다.
약물 유형
- 브랜드화
- 일반적인
북미와 유럽의 여성 건강 시장은 약물 유형을 기준으로 브랜드 제품과 제네릭 제품으로 구분됩니다.
케어 유형
- 일반 건강 관리 및 웰빙
- 임신 및 간호 관리
- 골반 및 자궁 건강 관리
- 기타
치료 유형을 기준으로 보면 북미와 유럽 여성 건강 시장은 일반 건강 관리 및 웰빙, 임신 및 간호 관리, 골반 및 자궁 건강 관리, 기타로 구분됩니다.
최종 사용자
- 병원 및 진료소
- 산부인과 센터
- 홈케어 설정
- 연구 기관
- 기타
북미와 유럽의 여성 건강 시장은 최종 사용자를 기준으로 병원 및 진료소, 산부인과 센터, 가정 간병 시설, 연구소 등으로 구분됩니다.
유통 채널
- 직접 입찰
- 소매 판매
- 온라인 판매
- 기타
북미와 유럽 여성 건강 시장은 유통 채널을 기준으로 직접 입찰, 소매 판매, 온라인 판매 및 기타 판매로 구분됩니다.
북미 및 유럽 여성 건강 시장 지역 분석/통찰력
북미와 유럽의 여성 건강 시장은 치료, 적응증, 전달 방식, 약물 유형, 케어 유형, 최종 사용자, 유통 채널을 기준으로 7개의 주요 세그먼트로 분류됩니다.
이 시장에서 다루는 국가는 미국, 캐나다, 멕시코, 독일, 프랑스, 이탈리아, 스페인, 스위스, 네덜란드, 벨기에, 러시아, 터키, 영국, 그리고 나머지 유럽 국가입니다.
북미는 이 지역의 R&D 활동의 결과로 혁신적인 기술이 개발됨에 따라 북미와 유럽 여성 건강 시장을 지배할 것으로 예상됩니다. 미국은 여성 건강 관리 부문을 위한 첨단 의료 인프라와 기술 혁신의 존재로 인해 북미 여성 건강 시장을 지배할 것으로 예상됩니다. 독일은 광범위한 유통망을 통해 국제 시장에서 강력한 입지를 확보하고 있어 유럽 여성 건강 시장을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 데이터 포인트 하류 및 상류 가치 사슬 분석, 기술 추세 포터의 5가지 힘 분석 및 사례 연구는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 지역 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세의 영향 및 무역 경로가 국가 데이터의 예측 분석을 제공하는 동안 고려됩니다.
북미 및 유럽 여성 건강 시장 점유율 분석
북미와 유럽 여성 건강 시장 경쟁 구도는 경쟁사별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.
북미 및 유럽 여성 건강 시장에서 활동하는 주요 기업으로는 Lilly, Abbott, Lupin, GSK plc., Novartis AG, AbbVie Inc., Noven Pharmaceuticals, Inc., Vertical Pharmaceuticals, LLC, Veru Inc., Pfizer Inc. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 INDUSTRY INSIGHTS
4.3.1 DRUG TREATMENT RATE IN MATURED MARKETS
4.3.2 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.3.3 PATIENT FLOW DIAGRAMS
4.3.4 KEY PRICING STRATEGIES
4.3.5 KEY ENROLLMENT STRATEGIES
4.4 PIPELINE ANALYSIS
4.5 PATENT DATA ANALYSIS
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN
5.1.2 INNOVATIVE TECHNOLOGIES BEING DEVELOPED AS AN AFTERMATH OF R&D ACTIVITIES
5.1.3 GOVERNMENT INITIATIVES TO IMPROVE OVERALL HEALTH AND WELLBEING
5.1.4 CHANGING LIFESTYLES AND ENVIRONMENTAL FACTORS IMPACTING HEALTH
5.2 RESTRAINTS
5.2.1 ADVERSE EFFECTS ASSOCIATED WITH CERTAIN PRODUCTS
5.2.2 STRICT REGULATIONS IMPOSED BY THE REGULATORY AGENCIES
5.3 OPPORTUNITIES
5.3.1 INCREASING RECOGNITION FOR MENTAL HEALTH
5.3.2 GROWING AWARENESS AND ACCEPTANCE OF FERTILITY TREATMENTS
5.3.3 GROWING INCIDENCES OF SEXUALLY TRANSMITTED DISEASES
5.4 CHALLENGES
5.4.1 ENVIRONMENTAL EXPOSURE IMPACTING REPRODUCTIVE HEALTH
5.4.2 HIGH MATERNAL MORTALITY AND MORBIDITY
6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 DRUGS
6.3 DEVICE
7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY INDICATION
7.1 OVERVIEW
7.2 CANCER
7.3 REPRODUCTIVE HEALTH
7.4 UROLOGICAL DISORDERS
7.5 HYPOTHYROIDISM
7.6 POST-MENOPAUSAL SYNDROME
7.7 OTHERS
8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE
8.1 OVERVIEW
8.2 GENERAL HEALTHCARE & WELLNESS
8.3 PREGNANCY & NURSING CARE
8.4 PELVIC & UTERINE HEALTHCARE
8.5 OTHERS
9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.3 GENERIC
10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DELIVERY MODE
10.1 OVERVIEW
10.2 PRESCRIPTION
10.3 OVER THE COUNTER
11 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS AND CLINICS
11.3 GYNECOLOGY CENTERS
11.4 HOMECARE SETTING
11.5 RESEARCH INSTITUTES
11.6 OTHERS
12 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDERS
12.3 RETAIL SALES
12.4 ONLINE SALES
12.5 OTHERS
13 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 CANADA
13.1.3 MEXICO
13.2 EUROPE
13.2.1 GERMANY
13.2.2 FRANCE
13.2.3 U.K.
13.2.4 ITALY
13.2.5 RUSSIA
13.2.6 SPAIN
13.2.7 TURKEY
13.2.8 NETHERLANDS
13.2.9 SWITZERLAND
13.2.10 BELGIUM
13.2.11 REST OF EUROPE
14 NORTH AMERICA AND EUROPE WOMEN HEALTH MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.2 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ABBOTT
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENT
16.2 ABBVIE INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENT
16.3 GSK PLC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENT
16.4 LILLY
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 LUPIN
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NOVARTIS AG
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENT
16.7 NOVEN PHARMACEUTICALS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENT
16.8 PFIZER INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 VERTICAL PHARMACEUTICALS, LLC
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 VERU INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
표 목록
TABLE 1 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DEVICES
TABLE 2 NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET, DRUGS
TABLE 3 PATENT DATA (1/4)
TABLE 4 PATENT DATA (2/4)
TABLE 5 PATENT DATA (3/4)
TABLE 6 PATENT DATA (4/4)
TABLE 7 NORTH AMERICA WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 8 EUROPE WOMEN’S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 EUROPE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 EUROPE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 14 EUROPE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 EUROPE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION
TABLE 18 EUROPE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 EUROPE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 EUROPE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 EUROPE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 EUROPE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 EUROPE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 EUROPE INSULIN-SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 32 EUROPE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 EUROPE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 EUROPE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 38 EUROPE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 40 EUROPE WOMEN’S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 EUROPE CANCER IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 NORTH AMERICA REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 EUROPE REPRODUCTIVE HEALTH IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 EUROPE UROLOGICAL DISORDERS IN WOMEN’S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 EUROPE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 50 EUROPE WOMEN’S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 EUROPE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 EUROPE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 EUROPE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 58 EUROPE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 59 NORTH AMERICA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 60 EUROPE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 61 NORTH AMERICA WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 EUROPE WOMEN’S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 NORTH AMERICA WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 EUROPE WOMEN’S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 65 NORTH AMERICA WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 66 U.S. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 67 U.S. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 U.S. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 U.S. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 U.S. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 U.S. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 72 U.S. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 U.S. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 U.S. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 U.S. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 U.S. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 77 U.S. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 U.S. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 U.S. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 U.S. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 U.S. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 83 U.S. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 U.S. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 85 U.S. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 U.S. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 U.S. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 88 U.S. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 89 U.S. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 90 U.S. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 U.S. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 U.S. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 U.S. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 94 U.S. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 95 CANADA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 96 CANADA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 CANADA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 CANADA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 CANADA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 CANADA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 101 CANADA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 102 CANADA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 CANADA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 CANADA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 CANADA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 CANADA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 107 CANADA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 CANADA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 110 CANADA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 111 CANADA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 112 CANADA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 CANADA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 114 CANADA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 CANADA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 CANADA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 117 CANADA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 118 CANADA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 119 CANADA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 CANADA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 121 CANADA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 122 CANADA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 123 CANADA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 124 MEXICO WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 125 MEXICO DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 MEXICO HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 127 MEXICO ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 MEXICO PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 MEXICO COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 MEXICO GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 MEXICO GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 MEXICO LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 MEXICO GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 MEXICO NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 135 MEXICO INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 136 MEXICO AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 MEXICO DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 MEXICO INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 MEXICO WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 141 MEXICO CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 MEXICO REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 MEXICO UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 MEXICO OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 145 MEXICO WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 146 MEXICO WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 147 MEXICO WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 148 MEXICO GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 MEXICO PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 150 MEXICO PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 151 MEXICO WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 MEXICO WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 EUROPE WOMEN'S HEALTH MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 154 GERMANY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 155 GERMANY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 GERMANY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 GERMANY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 GERMANY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 GERMANY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 160 GERMANY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 161 GERMANY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 GERMANY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 GERMANY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 164 GERMANY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 GERMANY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 GERMANY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 167 GERMANY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 168 GERMANY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 GERMANY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 170 GERMANY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 171 GERMANY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 172 GERMANY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 GERMANY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 GERMANY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 175 GERMANY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 176 GERMANY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 177 GERMANY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 178 GERMANY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 GERMANY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 GERMANY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 GERMANY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 182 GERMANY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 183 FRANCE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 184 FRANCE DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 185 FRANCE HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 186 FRANCE ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 FRANCE PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 FRANCE COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 FRANCE GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 FRANCE GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 FRANCE LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 192 FRANCE GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 193 FRANCE NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 FRANCE INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 195 FRANCE AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 196 FRANCE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 FRANCE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 FRANCE INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 199 FRANCE WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 200 FRANCE CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 201 FRANCE REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 202 FRANCE UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 FRANCE OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 FRANCE WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 205 FRANCE WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 206 FRANCE WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 207 FRANCE GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 208 FRANCE PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 FRANCE PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 210 FRANCE WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 211 FRANCE WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 212 U.K. WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 213 U.K. DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 U.K. HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 215 U.K. ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 U.K. PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 217 U.K. COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 218 U.K. GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 U.K. GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 220 U.K. LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 U.K. GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 U.K. NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 U.K. INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 U.K. AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 225 U.K. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 226 U.K. DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 227 U.K. INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 U.K. WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 229 U.K. CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 U.K. REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 U.K. UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 232 U.K. OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 233 U.K. WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 234 U.K. WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 235 U.K. WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 236 U.K. GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 U.K. PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 U.K. PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 239 U.K. WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 240 U.K. WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 241 ITALY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 242 ITALY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 243 ITALY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 ITALY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 245 ITALY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 246 ITALY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 ITALY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 ITALY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 ITALY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 250 ITALY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 251 ITALY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 252 ITALY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 ITALY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 ITALY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 ITALY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 ITALY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 257 ITALY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 258 ITALY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 ITALY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 260 ITALY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 261 ITALY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 ITALY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 263 ITALY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 264 ITALY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 265 ITALY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 ITALY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 267 ITALY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 268 ITALY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 269 ITALY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 270 RUSSIA WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 271 RUSSIA DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 272 RUSSIA HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 RUSSIA ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 RUSSIA PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 275 RUSSIA COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 276 RUSSIA GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 277 RUSSIA GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 RUSSIA LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 RUSSIA GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 RUSSIA NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 RUSSIA INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 RUSSIA AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 283 RUSSIA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 RUSSIA DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 285 RUSSIA INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 286 RUSSIA WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 287 RUSSIA CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 RUSSIA REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 289 RUSSIA UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 290 RUSSIA OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 RUSSIA WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 292 RUSSIA WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 293 RUSSIA WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 294 RUSSIA GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 295 RUSSIA PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 296 RUSSIA PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 297 RUSSIA WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 298 RUSSIA WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 299 SPAIN WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 300 SPAIN DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 301 SPAIN HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 302 SPAIN ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 SPAIN PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 304 SPAIN COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 305 SPAIN GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 306 SPAIN GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 307 SPAIN LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 308 SPAIN GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 309 SPAIN NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 310 SPAIN INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 311 SPAIN AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 312 SPAIN NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 313 SPAIN DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 314 SPAIN INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 315 SPAIN WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 316 SPAIN CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 317 SPAIN REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 318 SPAIN UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 319 SPAIN OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 320 SPAIN WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 321 SPAIN WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 322 SPAIN WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 323 SPAIN GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 324 SPAIN PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 325 SPAIN PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 326 SPAIN WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 327 SPAIN WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 328 TURKEY WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 329 TURKEY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 330 TURKEY HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 331 TURKEY ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 332 TURKEY PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 333 TURKEY COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 334 TURKEY GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 335 TURKEY GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 336 TURKEY LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 337 TURKEY GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 338 TURKEY NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 339 TURKEY INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 340 TURKEY AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 341 TURKEY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 342 TURKEY DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 343 TURKEY INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 344 TURKEY WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 345 TURKEY CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 346 TURKEY REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 347 TURKEY UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 348 TURKEY OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 349 TURKEY WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 350 TURKEY WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 351 TURKEY WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 352 TURKEY GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 353 TURKEY PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 354 TURKEY PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 355 TURKEY WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 356 TURKEY WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 357 NETHERLANDS WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 358 NETHERLANDS DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 359 NETHERLANDS HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 360 NETHERLANDS ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 361 NETHERLANDS PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 362 NETHERLANDS COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 363 NETHERLANDS GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 364 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 365 NETHERLANDS LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 366 NETHERLANDS GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 367 NETHERLANDS NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 368 NETHERLANDS INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 369 NETHERLANDS AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 370 NETHERLANDS NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 371 NETHERLANDS DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 372 NETHERLANDS INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 373 NETHERLANDS WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 374 NETHERLANDS CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 375 NETHERLANDS REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 376 NETHERLANDS UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 377 NETHERLANDS OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 378 NETHERLANDS WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 379 NETHERLANDS WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 380 NETHERLANDS WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 381 NETHERLANDS GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 382 NETHERLANDS PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 383 NETHERLANDS PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 384 NETHERLANDS WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 385 NETHERLANDS WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 386 SWITZERLAND WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 387 SWITZERLAND DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 388 SWITZERLAND HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 389 SWITZERLAND ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 390 SWITZERLAND PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 391 SWITZERLAND COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 392 SWITZERLAND GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 393 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 394 SWITZERLAND LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 395 SWITZERLAND GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 396 SWITZERLAND NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 397 SWITZERLAND INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 398 SWITZERLAND AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 399 SWITZERLAND NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 400 SWITZERLAND DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 401 SWITZERLAND INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 402 SWITZERLAND WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 403 SWITZERLAND CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 404 SWITZERLAND REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 405 SWITZERLAND UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 406 SWITZERLAND OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 407 SWITZERLAND WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 408 SWITZERLAND WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 409 SWITZERLAND WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 410 SWITZERLAND GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 411 SWITZERLAND PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 412 SWITZERLAND PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 413 SWITZERLAND WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 414 SWITZERLAND WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 415 BELGIUM WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
TABLE 416 BELGIUM DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 417 BELGIUM HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 418 BELGIUM ESTROGEN IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 419 BELGIUM PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 420 BELGIUM COMBINED ESTROGENS & PROGESTERONE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 421 BELGIUM GONADOTROPINS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 422 BELGIUM GONADOTROPIN-RELEASING HORMONE ANALOGS (GNRH ANALOGS) IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 423 BELGIUM LEUPROLIDE ACETATE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 424 BELGIUM GONADOTROPIN-RELEASING HORMONE ANTAGONIST IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 425 BELGIUM NON-HORMONAL TREATMENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 426 BELGIUM INSULIN SENSITIZING AGENT IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 427 BELGIUM AROMATASE INHIBITORS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 428 BELGIUM NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 429 BELGIUM DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 430 BELGIUM INTRA UTERINE DEVICE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 431 BELGIUM WOMEN'S HEALTH MARKET, BY INDICATION, 2022-2031 (USD MILLION)
TABLE 432 BELGIUM CANCER IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 433 BELGIUM REPRODUCTIVE HEALTH IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 434 BELGIUM UROLOGICAL DISORDERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 435 BELGIUM OTHERS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 436 BELGIUM WOMEN'S HEALTH MARKET, BY DELIVERY MODE, 2022-2031 (USD MILLION)
TABLE 437 BELGIUM WOMEN'S HEALTH MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 438 BELGIUM WOMEN'S HEALTH MARKET, BY CARE TYPE, 2022-2031 (USD MILLION)
TABLE 439 BELGIUM GENERAL HEALTHCARE & WELLNESS IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 440 BELGIUM PREGNANCY & NURSING CARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 441 BELGIUM PELVIC & UTERINE HEALTHCARE IN WOMEN'S HEALTH MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 442 BELGIUM WOMEN'S HEALTH MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 443 BELGIUM WOMEN'S HEALTH MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 444 REST OF EUROPE WOMEN'S HEALTH MARKET, BY TREATMENT, 2022-2031 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET: SEGMENTATION
FIGURE 11 THE RISING RATES OF CHRONIC DEBILITATING CONDITIONS AMONG WOMEN IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET FROM 2024 TO 2031
FIGURE 12 THE TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA AND EUROPE WOMEN’S HEALTH MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGE OF NORTH AMERICA AND EUROPE WOMEN'S HEALTH MARKET
FIGURE 14 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 15 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 16 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 17 NORTH AMERICA WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 18 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2023
FIGURE 19 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, 2024-2031 (USD MILLION)
FIGURE 20 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, CAGR (2024-2031)
FIGURE 21 EUROPE WOMEN’S HEALTH MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 22 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 23 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 24 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 25 NORTH AMERICA WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 26 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2023
FIGURE 27 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, 2024-2031 (USD MILLION)
FIGURE 28 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, CAGR (2024-2031)
FIGURE 29 EUROPE WOMEN’S HEALTH MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 31 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 32 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 33 NORTH AMERICA WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 34 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2023
FIGURE 35 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, 2024-2031 (USD MILLION)
FIGURE 36 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, CAGR (2024-2031)
FIGURE 37 EUROPE WOMEN’S HEALTH MARKET: BY CARE TYPE, LIFELINE CURVE
FIGURE 38 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 39 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 40 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 41 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 42 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2023
FIGURE 43 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 44 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 45 EUROPE WOMEN’S HEALTH MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 46 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 47 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 48 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 49 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 50 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2023
FIGURE 51 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, 2024-2031 (USD MILLION)
FIGURE 52 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, CAGR (2024-2031)
FIGURE 53 EUROPE WOMEN’S HEALTH MARKET: BY DELIVERY MODE, LIFELINE CURVE
FIGURE 54 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 55 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 56 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 57 NORTH AMERICA WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 58 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2023
FIGURE 59 EUROPE WOMEN’S HEALTH MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 60 EUROPE WOMEN’S HEALTH MARKET: BY END USER, CAGR (2024-2031)
FIGURE 61 EUROPE WOMEN’S HEALTH MARKET: BY END USER, LIFELINE CURVE
FIGURE 62 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 63 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 64 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 65 NORTH AMERICA WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 66 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 67 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 68 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 69 EUROPE WOMEN’S HEALTH MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 70 NORTH AMERICA WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 71 EUROPE WOMEN'S HEALTH MARKET: SNAPSHOT (2023)
FIGURE 72 NORTH AMERICA WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
FIGURE 73 EUROPE WOMEN HEALTH MARKET: COMPANY SHARE 2023 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
